Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

NCT06555146 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests how semaglutide affects kidney function and blood flow in adults with type 2 diabetes and chronic kidney disease.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 15 people Planned (estimated).

Who can join Ages 20–60 · male only

Timeline Started 2024-08 · est. completion 2025-03

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT06555146 ↗

Description as written by the study sponsor.

The goal of this double-blinded, placebo-controlled, randomized, crossover study is to examine the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on renal hemodynamics and function in patients with type 2 diabetes mellitus (T2DM) and moderate chronic kidney disease (CKD). The study will determine the effects of semaglutide on: * Renal arterial blood flow, regional renal perfusion, and oxygenation * Activity of the renin-angiotensin-aldosterone system (RAAS) * The glomerular filtration rate (GFR) * Sodium excretion in urine * Blood pressure and heart rate

Treatments tested

Semaglutide, 0.5 mg/mL Drug

1 subcutaneous injection on baseline day
Placebo, Saline Drug

1 subcutaneous injection on baseline day

Main thing measured	Total blood flow
Sponsor	Bispebjerg Hospital
Conditions studied	Diabetes Mellitus, Type 2, Kidney Disease, Chronic
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06555146 ↗